JP7116884B2 - 改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法 - Google Patents

改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法 Download PDF

Info

Publication number
JP7116884B2
JP7116884B2 JP2019531572A JP2019531572A JP7116884B2 JP 7116884 B2 JP7116884 B2 JP 7116884B2 JP 2019531572 A JP2019531572 A JP 2019531572A JP 2019531572 A JP2019531572 A JP 2019531572A JP 7116884 B2 JP7116884 B2 JP 7116884B2
Authority
JP
Japan
Prior art keywords
weeks
cells
cell
light
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528781A (ja
JP2019528781A5 (https=
Inventor
パン，チュオ－ファ
ガンジャワラ，トゥーシャー
ルー，チー
アブラムズ，ゲアリー
Original Assignee
ウェイン・ステイト・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイン・ステイト・ユニバーシティ filed Critical ウェイン・ステイト・ユニバーシティ
Publication of JP2019528781A publication Critical patent/JP2019528781A/ja
Publication of JP2019528781A5 publication Critical patent/JP2019528781A5/ja
Application granted granted Critical
Publication of JP7116884B2 publication Critical patent/JP7116884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019531572A 2016-08-29 2017-08-29 改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法 Active JP7116884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380871P 2016-08-29 2016-08-29
US62/380,871 2016-08-29
PCT/US2017/049158 WO2018044912A1 (en) 2016-08-29 2017-08-29 Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019528781A JP2019528781A (ja) 2019-10-17
JP2019528781A5 JP2019528781A5 (https=) 2020-09-24
JP7116884B2 true JP7116884B2 (ja) 2022-08-12

Family

ID=59859616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531572A Active JP7116884B2 (ja) 2016-08-29 2017-08-29 改善された光感受性を有するチャネルオプシン変異体における突然変異の特定及びその使用方法

Country Status (15)

Country Link
US (3) US11041004B2 (https=)
EP (1) EP3504227A1 (https=)
JP (1) JP7116884B2 (https=)
KR (3) KR102609571B1 (https=)
CN (2) CN110023327B (https=)
AU (4) AU2017319306B2 (https=)
BR (1) BR112019003950A2 (https=)
CA (1) CA3034887A1 (https=)
IL (2) IL265010B2 (https=)
MX (1) MX2019002321A (https=)
MY (1) MY197491A (https=)
NZ (1) NZ751983A (https=)
RU (1) RU2019109021A (https=)
SG (2) SG10202102061SA (https=)
WO (1) WO2018044912A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN113173984B (zh) 2021-04-12 2022-08-30 中眸医疗科技(武汉)有限公司 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用
MX2024007770A (es) * 2021-12-20 2024-07-01 Genans Biotechnology Co Ltd Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5).
EP4665750A1 (en) 2023-02-17 2025-12-24 Ray Therapeutics, Inc. Gene therapy compositions and methods for treating diseases of the retina
WO2025137649A1 (en) * 2023-12-22 2025-06-26 Wayne State University Method of enhancing viral mediated gene delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150223679A1 (en) 2014-02-07 2015-08-13 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof
JP2016519063A (ja) 2013-03-14 2016-06-30 ウェイン ステイト ユニバーシティー 治療用化合物の眼への送達を増強する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
CN101484005A (zh) 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
KR100922422B1 (ko) 2006-06-27 2009-10-16 가부시키가이샤 어드밴테스트 반도체 시험 장치 및 반도체 메모리의 시험 방법
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
KR101945962B1 (ko) 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
WO2013071231A1 (en) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsins for optical control of cells
CA2866405A1 (en) * 2012-03-05 2013-09-12 Wayne State University Identification of channelopsin-2 (chop2) mutations and methods of use
EP4678754A3 (en) 2014-03-11 2026-04-08 Wayne State University A modified mglur6 promoter and methods of use
WO2015161308A1 (en) 2014-04-18 2015-10-22 Massachusetts Institute Of Technology Mutant channelrhodopsins with altered ion selectivity
WO2016179038A1 (en) 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
LT3436051T (lt) 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
WO2017210664A1 (en) 2016-06-03 2017-12-07 Massachusetts Institute Of Technology Somatic opsins for single cell resolution optogenetics
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3504227A1 (en) 2016-08-29 2019-07-03 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519063A (ja) 2013-03-14 2016-06-30 ウェイン ステイト ユニバーシティー 治療用化合物の眼への送達を増強する方法
US20150223679A1 (en) 2014-02-07 2015-08-13 Massachusetts Institute Of Technology Blue light-activated ion channel molecules and uses thereof

Also Published As

Publication number Publication date
IL265010B1 (en) 2024-02-01
SG11201901697QA (en) 2019-03-28
US11041004B2 (en) 2021-06-22
RU2019109021A (ru) 2020-09-29
WO2018044912A1 (en) 2018-03-08
KR102609571B9 (ko) 2025-11-20
IL310142A (en) 2024-03-01
EP3504227A1 (en) 2019-07-03
JP2019528781A (ja) 2019-10-17
AU2024200016B2 (en) 2025-07-17
AU2024200016A1 (en) 2024-01-25
BR112019003950A2 (pt) 2019-06-25
CA3034887A1 (en) 2018-03-08
KR20250159068A (ko) 2025-11-07
US20250163111A1 (en) 2025-05-22
US12234267B2 (en) 2025-02-25
KR20230169427A (ko) 2023-12-15
NZ751983A (en) 2025-11-28
AU2022201291B2 (en) 2023-10-05
MY197491A (en) 2023-06-19
IL265010A (https=) 2019-04-30
AU2024200016B9 (en) 2025-08-07
KR20190075906A (ko) 2019-07-01
KR102609571B1 (ko) 2023-12-01
AU2017319306B2 (en) 2021-12-02
AU2022201291A1 (en) 2022-03-17
CN119979612A (zh) 2025-05-13
MX2019002321A (es) 2019-10-21
US20220089660A1 (en) 2022-03-24
SG10202102061SA (en) 2021-04-29
US20190241628A1 (en) 2019-08-08
RU2019109021A3 (https=) 2021-02-02
AU2025248765A1 (en) 2025-10-30
AU2017319306A1 (en) 2019-04-11
IL265010B2 (en) 2024-06-01
KR102877327B1 (ko) 2025-10-27
CN110023327B (zh) 2024-02-27
CN110023327A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
US12234267B2 (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AU2013257450B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
ES2741502T3 (es) Cápside de AAV8 modificada para la transferencia génica para terapias de retina
EP3117002B1 (en) A modified mglur6 promoter and methods of use
ES2908467T3 (es) Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante
JP2023529503A (ja) 網膜症のためのａａｖ媒介性遺伝子導入
US20220088222A1 (en) Compositions and methods for the treatment of degenerative ocular diseases
BR122024010814A2 (pt) Vetor de expressão de vírus adeno-associado (aav) ou de vírus adenoassociado recombinante (raav), composição farmacêutica, usos dos mesmos, e método para alterar a condutividade de uma membrana
WO2025137649A1 (en) Method of enhancing viral mediated gene delivery
CN117980489A (zh) Retgc基因疗法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220413

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220712

R150 Certificate of patent or registration of utility model

Ref document number: 7116884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250